Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Aberrant NRF2-Dependent Cytoprotection Subverts Stress Homeostasis and Promotes Tumor Progression.

Created on 15 Nov 2026

Authors

Gaoqing Feng, Yuhong Yang, Huahua Wang, Mao Du, Qin Xia, Lei Dong

Published in

Current issues in molecular biology. Volume 48. Issue 10. Oct 03, 2026. Epub Oct 03, 2026.

Abstract

Nuclear factor erythroid 2-related factor 2 (NRF2) coordinates antioxidant defense, metabolism, iron homeostasis, and proteostasis to support cellular adaptation to stress. Kelch-like ECH-associated protein 1 (KEAP1)-Cullin 3 (CUL3) continuously targets NRF2 for proteasomal degradation. Oxidative or electrophilic stress modifies sensor cysteines in KEAP1, transiently attenuating degradation and allowing NRF2 to stabilize and accumulate in the nucleus. Complementary KEAP1-independent mechanisms limit excessive or prolonged NRF2 activity, including glycogen synthase kinase 3 (GSK3)/β-transducin repeat-containing protein (β-TrCP)-mediated degradation and SMAD-specific E3 ubiquitin-protein ligase 2 (SMURF2)-mediated nuclear clearance. In cancer, genetic, epigenetic, and signaling alterations can disable these restraints and sustain NRF2 activity. Persistent NRF2 signaling increases cancer-cell stress tolerance by supporting antioxidant defense, metabolic adaptation, proteostasis, and resistance to therapy. This review examines the spatial and context-dependent control of NRF2 by KEAP1-CUL3, GSK3/β-TrCP, and SMURF2 and considers how failure to terminate cytoprotective signaling supports tumor progression.

PMID:
42939562
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement